Carcinogenesis Advance Access originally published online on April 24, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis, Vol. 24, No. 6, 1059-1065,
June 2003
© 2003 Oxford University Press
CANCER BIOLOGY |
Sex difference in the proliferative response of mouse hepatocytes to treatment with the CAR ligand, TCPOBOP
Department of Toxicology, Oncology and Molecular Pathology Unit, University of Cagliari, Via Porcell 4, 09124 Cagliari, Italy
1 To whom correspondence should be addressed Email: gmledda{at}unica.it
The nuclear receptor Constitutive Androstane Receptor (CAR) binds DNA as a heterodimer with the retinoic-X receptor and activates gene transcription. Previously, in vitro studies have shown that the testosterone metabolites, androstanol and androstenol, inhibit the constitutive transcriptional activity of CAR, suggesting that differences might exist in the response to CAR-mediated gene activation between different sexes. In this study, we have analyzed the response of female and male CD-1 mice to stimulation of hepatocyte proliferation caused by the CAR ligand TCPOBOP. Results showed that the labelling index of female hepatocytes at 24, 30 and 36 h after treatment was much higher than that found in males. The higher proliferative activity of female hepatocytes was associated with increased hepatic levels of cyclin D1, cyclin A, E2F and enhanced phosphorylation of pRb and p107. The increased mitogenic response of females was associated with higher mRNA levels of CYP2B10, a known target of CAR. Administration of androstanol to TCPOBOP-treated mice caused a reduction of labelling index, which was accompanied by a decrease of CYP2B10 and CAR mRNA levels. In conclusion, the results show that, in addition to microsomal detoxification, another biological response elicited by the CAR ligand TCPOBOP, namely, hepatocyte proliferation, occurs at higher levels in female than male mice, suggesting that CAR transcriptional activity in males is partially counteracted by physiological higher levels of testosterone metabolites such as androstanol and androstenol.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Braeuning, R. Sanna, J. Huelsken, and M. Schwarz Inducibility of Drug-Metabolizing Enzymes by Xenobiotics in Mice with Liver-Specific Knockout of Ctnnb1 Drug Metab. Dispos., May 1, 2009; 37(5): 1138 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Al Kholaifi, A. Amer, B. Jeffery, T. J. B. Gray, R. A. Roberts, and D. R. Bell Species-Specific Kinetics and Zonation of Hepatic DNA Synthesis Induced by Ligands of PPAR{alpha} Toxicol. Sci., July 1, 2008; 104(1): 74 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Alnouti and C. D. Klaassen Regulation of Sulfotransferase Enzymes by Prototypical Microsomal Enzyme Inducers in Mice J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 612 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Petrick and C. D. Klaassen Importance of Hepatic Induction of Constitutive Androstane Receptor and Other Transcription Factors That Regulate Xenobiotic Metabolism and Transport Drug Metab. Dispos., October 1, 2007; 35(10): 1806 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Swales and M. Negishi CAR, Driving into the Future Mol. Endocrinol., July 1, 2004; 18(7): 1589 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF]
|
|